Studies show that in NSCLC, PRMT5 plays a key role in chemotherapy-induced NED, and targeting PRMT5 effectively restores sensitivity to etoposide in NSCLC cells (100). This evidence concerns the gene PRMT5 and non-small cell lung carcinoma.